You just read:

AbbVie Presents Phase 3 Data Demonstrating Efficacy and Safety of HUMIRA® (adalimumab) in Children and Adolescents with Severe Chronic Plaque Psoriasis at the 23rd World Congress of Dermatology

News provided by

AbbVie

09 Jun, 2015, 17:00 BST